Ramiro Sanchez - 15 Dec 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Medical Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: CERE
Transactions as of: 15 Dec 2023
Transactions value $: -$236,293
Form type: 4
Filing time: 19 Dec 2023, 16:15:15 UTC
Previous filing: 11 Dec 2023
Next filing: 21 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$74.1K	+7.5K		$9.88	7.5K	15 Dec 2023	Direct
transaction	CERE	Common Stock	Sale	-$310K	-7.5K	-100%	$41.39	0	15 Dec 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-7.5K	-5.73%	$0.00	123K	15 Dec 2023	Common Stock	7.5K	$9.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter.